Contemporary Trends of the Adjutant Chemotherapy in Non‑ small Cell Lung Cancer

Česká verzia

Authors: V. Kolek
Authors place of work: Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc
Published in the journal: Klin Onkol 2013; 26(4): 245-250
Category: Přehledy

Summary

Background:
Adjuvant chemotherapy became a standard of treatment in completely resected non-small cell lung cancer (NSCLC) based on results of big trials meta-analyses, which proved its influence on the decrease of relative mortality risk and absolute improvement of survival. Adjuvant chemotherapy is routinely used according to tumor stage evaluation, performance status (PS) and age of the patients. It is indicated in stage II and IIIA of NSCLC– in frame of clinical studies also in stage IB, in PS 0–1 and in patients under 75 years. Therapy with cisplatin and vinorelbine is a preferred regimen, as well as other drugs, such as paclitaxel, docetaxel, gemcitabine and pemetrexed. The problem is a relatively small dose intensity applied, due to toxic side effects.

Aim:
The present work is evaluating contemporary trends of adjuvant therapy in NSCLC according to latest clinical studies, which are finished or running. Efforts are directed to the improvement of treatment effectiveness, decrease of side effects and refinement of patients selection. Potential treatment benefit of better tolerable carboplatin is verified and results of trials with biologically targeted therapy are expected. Large clinical studies are evaluating the effect of tyrosine kinase inhibitors and angiogenesis inhibitors used either in various combinations with chemotherapy or as monotherapy. Application of vaccines is tested.

Conclusion:
Contemporary trend of adjuvant therapy is leading to the appropriate patient selection with regard to analysis of several prognostic and predictive biomarkers; it is proposed that future adjuvant therapy will be more and more personalized.

Key words:
non-small cell lung cancer – early stage – adjuvant chemotherapy – molecular targeted therapy

Zdroje

1. Coello MC, Luketich JD, Litle VR et al. Prognostic significance of micrometastasis in non‑small‑cell lung cancer. Clin Lung Cancer 2004; 5(4): 214– 225.

2. Siegel R, Ward E, Brawley O et al. Cancer Statistics, 2011: the impact on eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212– 236.

3. Non‑ small Cell Lung Cancer Collaborative Group. Chemotherapy in non‑small cell lung cancer: A meta‑analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311(7010): 899– 909.

4. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26(21): 3552– 3559.

5. Scagliotti GV, Fossati R, Torri V et al. Randomized study of adjuvant chemotherapy for completely resected stage I,II, or IIIA non‑small cell lung cancer. J Natl Cancer Inst 2003; 95(19): 1453– 1461.

6. Waller D, Peake MD, Stephens RJ et al. Chemotherapy for patients with non‑small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004; 26(1): 173– 182.

7. Arriagada R, Bergman B, Dunant A et al. Cisplatin‑based adjuvant chemotherapy in patients with completely resected non‑small cell lung cancer. N Engl J Med 2004; 350(4): 351– 360.

8. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB‑ IIIA non‑small‑cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7(9): 719– 727.

9. Bria E, Gralla RJ, Raftopoulos H et al. Magnitude of benefit of adjuvant chemotherapy for non‑small cell lung cancer: meta‑analysis of randomized clinical trials. Lung Cancer 2009; 63(1): 50– 57.

10. Sedrakyan A, Van Der Meulen J, O‘Byrne K et al. Postoperative chemotherapy for non‑small cell lung cancer: A systematic review and meta‑analysis. J Thorac Cardiovasc Surg 2004; 128(3): 414– 419.

11. PORT meta‑analysis trialists group. Postoperative radiotherapy in non‑small‑cell lung cancer: systematic review and meta‑analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352(9124): 257– 263.

12. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non‑small‑cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000; 343(17): 1217– 1222.

13. Sawyer TE, Bonner JA, Gould PM et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 1997; 80(8): 1399– 1408.

14. Lally BE, Zelterman D, Colasanto JM et al. Postoperative radiotherapy for stage II or III non‑small‑cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24(19): 2998– 3006.

15. Machtay M, Lee JH, Shrager JB et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high‑risk resected non‑small‑cell lung carcinoma. J Clin Oncol 2001; 19(19): 3912– 3917.

16. Ettinger DS, Akerley W, Bepler G et al. NCCN Non‑ Small Cell Lung Cancer Panel Members. Non Small Cell Lung Cancer. J Natl Compr Canc Netw 2010; 8(7): 740– 801.

17. Imaizumi M. Study Group of Adjutant Chemotherapy for Lung Cancor. Postoperative adjuvant cisplatin, vindesine, plus uracil‑ tegafur chemotherapy increased survival of patients with completely resected p‑stage I non‑small cell lung cancer. Lung Cancer 2005; 49(1): 85– 94.

18. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil‑ tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350(17): 1713– 1721.

19. Hamada C, Tanaka F, Ohta M et al. Meta‑analysis of postoperative adjuvant chemotherapy with tegafur‑ uracil in non‑small‑cell lung cancer. J Clin Oncol 2005; 23(22): 4999– 5006.

20. Kreuter M, Vansteenkiste J, Fischer JR et al. Randomized phase II trial on refinement of early‑stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed vs cisplatin and vinorelbine: the TREAT study. Ann Oncol 2013; 24(4): 986– 992.

21. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs observation in resected non‑small‑cell lung cancer. N Engl J Med 2005; 352(25): 2589– 2597.

22. Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007; 25(12): 1553– 1561.

23. Wisnivesky JP, Smith CB, Packer S et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II– IIIA lung cancer: observational cohort study. BMJ 2011; 343: d4013.

24. Arriagada R, Dunant A, Pignon JP et al. Long‑term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin‑based chemotherapy in resected lung cancer. J Clin Oncol 2010; 28(1): 35– 42.

25. Butts CA, Ding K, Seymour L et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non‑small‑cell lung cancer: updated survival analysis of JBR‑ 10. J Clin Oncol 2010; 28(1): 29– 34.

26. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin‑versus carboplatin‑based chemotherapy in first‑line treatment of advanced non‑small‑cell lung cancer: an individual patient data meta‑analysis. J Natl Cancer Inst 2007; 99(11): 847– 857.

27. Hotta K, Matsuo K, Ueoka H et al. Meta‑analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non‑small‑cell lung cancer. J Clin Oncol 2004; 22(19): 3852– 3859.

28. Strauss GM, Herndon JE 2nd, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non‑small‑cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26(31): 5043– 5051.

29. Sun H, Wang S, Ou W et al. A prospective randomized study of adjuvant chemoterapy in resected stage IIIA‑ N2 non‑small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009; 12(9): 975– 982.

30. Karapanagiotou EM, Boura PG, Papamichalis G et al. Carboplatin‑pemetrexed adjuvant chemotherapy in resected non‑small cell lung cancer (NSCLC): a phase II study. Anticancer Res 2009; 29(10): 4297– 4301.

31. Stinchcombe TE, Harper HD, Hensing TA et al. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non‑small cell lung cancer. J Thorac Oncol 2008; 3(2): 145– 151.

32. Younis T, Al‑ Fayea T, Virik K et al. Adjuvant chemotherapy uptake in non‑small cell Lung cancer. J Thorac Oncol 2008; 3(11): 1272– 1278.

33. Kolek V, Grygárková I, Chalupa J et al. Možnosti podání perorálního vinorelbinu v adjuvantní chemoterapii u nemalobuněčného karcinomu plic. Multicentrická studie proveditelnosti a snášenlivosti. Stud Pneumol Phtiseol 2010; 70(3): 102– 105.

34. Kolek V, Chalupa J, Grygárková I et al. Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non‑small cell lung cancer: A prospective multicentre study of feasibility and tolerability. J Thorac Oncol 2011; 6(6): S1330.

35. Gu F, Strauss GM, Wisnivesky JP. Platinum‑based adjuvant chemotherapy (ACT) in elderly patients with non‑small cell lung cancer (NSCLC) in the SEER‑ Medicare database: Comparison between carboplatin‑ and cisplatin‑based regimens. J Clin Oncol 2011; 29 (Suppl 15): 7014.

36. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non‑small‑cell lung cancer and cisplatin‑based adjuvant chemotherapy. N Engl J Med 2006; 355(10): 983– 991.

37. Simon GR, Sharma S, Cantor A et al. ERCC1 expression is a predictor of survival in resected patients with non‑small cell lung cancer. Chest 2005; 127(3): 978– 983.

38. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356(8): 800– 808.

39. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non‑small‑cell lung cancer. J Clin Oncol 2006; 24(29): 4731– 4737.

40. Rosell R, Perez‑ Roca L, Sanchez JJ et al. Customized treatment in non‑small‑cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. Plos One 2009; 4(5): e5133– e5133.

41. Tsao MS, Aviel‑ Ronen S, Ding K et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small‑cell lung cancer. J Clin Oncol 2007; 25(33): 5240– 5247.

42. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non‑small‑cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23(25): 5900– 5909.

43. Sève P, Lai R, Ding K et al. Class III beta‑tubulin expression and benefit from adjuvant cisplatin/ vinorelbine chemotherapy in operable non‑small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007; 13(3): 994– 999.

44. Graziano SL, Gu L, Wang X et al. Prognostic significance of mucin and p53 expression in stage IB non‑small cell lung cancer: A laboratory companion study to CALGB 9633. J Thorac Oncol 2010, 5(6): 810– 817.

45. Filipits M, Haddad V, Schmid K et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non‑small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 2007; 13(13): 3892– 3898.

46. Skrzypski M, Jassem E, Taron M et al. Three‑ gene expression signature predicts survival in early‑stage squamous cell carcinoma of the lung. Clin Cancer Res 2008; 14(15): 4794– 4799.

47. Yanagisawa K, Tomida S, Shimada Y et al. A 25- signal proteomic signature and outcome for patients with resected non‑small‑cell lung cancer. J Natl Cancer Inst 2007; 99(11): 858– 867.

48. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early‑stage non‑small‑cell lung cancer. N Engl J Med 2006; 355(6): 570– 580.

49. Zhu CQ, Ding K, Strumpf D et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non‑small‑cell lung cancer. J Clin Oncol 2010; 28(29): 4417– 4424.

50. Kolek V, Grygarková I, Hajdúch M et al. Long term follow‑up of neoadjuvant‑ adjuvant combination treatment of IIIA stage non‑ small‑cell‑ lung cancer: Results of neoadjuvants of carboplatin/ vinorelbin and carboplatin/ paclitaxel regiment combined with selective adjutant chemotherapy according to in vitro chemoresistance test. Olomouc: Biomed Pap UP 2008; 152(2): 259– 266.

51.Goss GD, Lorimer I, Tsao MS et al. A phase III randomized, double‑blind, placebo‑ controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB‑ IIIA non‑small cell lung cancer (NSCLC): NCIC CTG BR.19. J Clin Oncol 2010; 28 (Suppl 18): abstr. LBA7005.

52. Tsao MS, Sakurada A, Ding K et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non‑small cell lung cancer. J Thorac Oncol 2011; 6(1): 139– 147.

53. Janjigian YY, Park BJ, Zakowski MF et al. Impact on disease‑free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 2011; 6(3): 569– 575.

54. Varella‑ Garcia M, Mitsudomi T, Yatabe Y et al. EGFR and HER2 genomic gain in recurrent non‑ small cell lung cancer after surgery impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese Cohort. J Thorac Oncol 2009; 4(3): 318– 325.

55. D‘Angelo SP, Janjigian YY, Ahye N et al. Distinct clinical course of EGFR‑ mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012; 7(12): 1815– 1822.

56. Wu YL (ed). Gefitinib Versus Vinorelbine/ Platinum as Adjuvant Treatment in Stage II– IIIA(N1– N2) NSCLC With EGFR Mutation (ADJUVANT) [monograph on the Internet]. Available from: http:/ / clinicaltrials.gov.

57. Wang SY, Sun H, Ou W et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non‑small cell lung cancer. Clin Lung Cancer 2013; 30 (Suppl): abstr. 7034.

58. Tada H, Takeda K, Nakagawa K et al. Vinorelbine plus cisplatin versus gefitinib in resected non‑small cell lung cancer harboring activating EGFR mutation (WJOG6410L). J Clin Oncol 2012; 30 (Suppl): abstr. TPS7110.

59. Neal JW, Pennell NA, Goodgame BW et al. A multicenter phase II trial of adjuvant erlotinib in patients with resected non‑small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation. J Clin Oncol 2010; 28 (Suppl 15): abstr. 7078.

60. Richardson F, Richardson K, Sennello G et al. Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). J Clin Oncol 2009; 27 (Suppl 15): 387.

61. Wakelee H, Dahlberg SE, Keller SM et al. Interim report of on‑ study demographics and toxicity from E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early‑stage non‑small cell lung cancor. J Clin Oncol 2011; 29 (Suppl): abstr. 7013.

62. Waterhouse DM, Hainsworth JD, Greco FA et al. Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non‑small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). J Clin Oncol 2012; 30 (Suppl): abstr. 7035.

63. Pujol JL, Vansteenkiste JF, De Pas TM et al. MAGE‑ A3 cancer immunotherapeutic in resected stage IB‑ III NSCLC patients with or without sequential or concurrent chemotherapy. J Clin Oncol 2012; 30 (Suppl): abstr. 7013.